Accueil・Liste d'Actions・Coherus Oncology Inc

Coherus Oncology Inc

Fermé

SecteurSoins de santé

1.32 -2.22

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.1400000000000001

Max

1.35

Chiffres clés
By Trading Economics
Revenu	-21M -59M
Ventes	2M 14M
P/E Moyenne du Secteur	3.509 57.371
BPA	-0.22
Marge bénéficiaire	-412.092
Employés	144
EBITDA	3.7M -30M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+478.36% upside

Dividendes
By Acuity
Prochains Résultats	5 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-44M 178M
Ouverture précédente	3.54
Clôture précédente	1.32

Sentiment de l'Actualité

By Acuity

50%

156 / 340 Classement par Healthcare

Coherus Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 août 2026, 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17 août 2026, 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14 août 2026, 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13 août 2026, 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12 août 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11 août 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10 août 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8 août 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

7 août 2026, 23:21 UTC

Coherus BioSciences Inc shares are rising in after-market trading, following a Labor Department report that reduced expectations for a Federal Reserve rate hike.

6 août 2026, 23:21 UTC

Coherus BioSciences Inc shares fell in after-market trading, reflecting ongoing weakness and volatility amid a lack of specific news to explain the decline.

5 août 2026, 23:01 UTC

News

Coherus BioSciences shares are lower in after-market trading following a second-quarter adjusted EPS of -$0.19, despite exceeding estimates. Sales missed expectations at $14.31 million.

4 août 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

3 août 2026, 19:44 UTC

Coherus BioSciences Inc shares are higher during Monday's session, continuing a notable advance since Friday's close, despite trading below its 20-day moving average.

31 juil. 2026, 20:06 UTC

Coherus BioSciences shares are lower today, amid rising U.S. Treasury yields and crude oil prices, which have heightened inflation concerns and interest rate expectations.

30 juil. 2026, 22:46 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting a positive response amid broader market recovery despite no specific company news identified.

29 juil. 2026, 18:46 UTC

Macro Event

Coherus BioSciences Inc shares are lower today amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

27 juil. 2026, 17:31 UTC

Coherus BioSciences Inc shares are higher during Monday's session, reflecting broader market trends amid declining oil prices that have eased inflation concerns.

23 juil. 2026, 19:56 UTC

Coherus BioSciences Inc is trading lower amid broader market concerns over corporate earnings and inflation pressures. Shares remain below their 20-day moving average.

22 juil. 2026, 18:26 UTC

Coherus BioSciences Inc shares are trading lower amid broader market pressures, remaining near the lower end of their one-month range. No specific news was identified.

21 juil. 2026, 19:41 UTC

Social Media

Coherus BioSciences Inc shares are higher as analysts set a $7 average price target, with potential for positive data readouts this month.

20 juil. 2026, 17:31 UTC

Coherus BioSciences Inc. shares are roughly flat today, showing little change since Friday's close amid routine trading activity within a one-month range.

Comparaison

Variation de prix

Coherus Oncology Inc prévision

Objectif de Prix

By TipRanks

478.36% hausse

Prévisions sur 12 Mois

Moyen 7.75 USD 478.36%

Haut 10 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

156 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.